• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Respiratory Inhalers Companies

    ID: MRFR/MED/2237-CR
    111 Pages
    Kinjoll Dey
    February 2021

    Respiratory inhaler companies develop and manufacture devices that deliver medications directly to the lungs, helping individuals with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) manage their symptoms. These companies play a crucial role in providing effective treatments and improving the quality of life for people with respiratory conditions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Respiratory Inhalers Market Research Report- Global Forecast To 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Respiratory Inhalers Market


    Respiratory Inhalers Key Companies*Disclaimer: List of key companies in no particular orderLatest Respiratory inhaler Companies Update


    • May 2023: To standardize and uniformly manage patients with severe asthma, the biopharmaceutical giant AstraZeneca India will create five Centers of Excellence in the cities of New Delhi, Ahmedabad, Goa, and Kochi. According to a press release, these facilities will "act as a hub for the treatment and management of severe asthma patients" and "assist emerging severe asthma centers" in their efforts to "identify and treat severe asthma patients in a systematic and guidelines-based manner.




    • July 2023: BreynaTM (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. FDA, was released by the global healthcare company Viatris Inc. and the specialty pharmaceutical company Kindeva Drug Delivery L.P. Breyna is a combination medication and inhaler that is now available in two different dose strengths: 80 mcg/4.5 mcg and 160 mcg/4.5 mcg, respectively, and is recommended for use by patients with asthma or chronic obstructive pulmonary disease (COPD).




    • July 2023: Teva introduced their first digitally-enabled inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in the United Kingdom in July 2023. The inhaled corticosteroid budesonide and long-acting beta agonist formoterol are delivered via the GoResp Digihaler, which incorporates sensors to track and record a patient's usage and efficacy. With a simple Bluetooth connection, the findings may be sent to a smartphone and seen there or sent to a doctor. Teva claims their new integrated inhaler is the first to have sensors that can detect and record objective data on the inhaler user, such as inspiratory flow measurements that may be used to categorize a patient's respiratory symptoms.


    List of Respiratory inhaler Key companies in the market


    • Teva Pharmaceutical Industries Ltd.




    • AstraZeneca




    • PARI Medical Holding




    • Beximco Pharmaceuticals Ltd.




    • OMRON Healthcare Europe




    • Boehringer Ingelheim GmbH




    • Merck & Co Inc.




    • GlaxoSmithKline plc




    • Cipla Ltd.




    • Koninklijke Philips N.V